Brii Biosciences Presents Hepatitis B Drug Data at European Medical Conference

MT Newswires Live06-10

Brii Biosciences (HKG:2137) presented new data from two phase 2 studies of BRII-179 for chronic hepatitis B virus infection at the European Association for the Study of the Liver Congress 2024, a June 7 filing on the Hong Kong bourse said.

The data presented showed that BRII-179, in combination with BRII-835, demonstrated antiviral effects in participants with chronic HBV infection.

Meanwhile, administering BRII-179 on top of pegylated interferon-alpha improved the overall HBsAg loss rate in 114 virally-suppressed subjects with chronic HBV infection.

Price (HKD): $1.26, Change: $-0.01, Percent Change: -0.79%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2442843850?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-10 19:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2442843850","market":"nz","top_or_hot":-1,"title":"Brii Biosciences Presents Hepatitis B Drug Data at European Medical Conference","media":"MT Newswires Live","content":"<html><body><p> Brii Biosciences (HKG:2137) presented new data from two phase 2 studies of BRII-179 for chronic hepatitis B virus infection at the European Association for the Study of the Liver Congress 2024, a June 7 filing on the Hong Kong bourse said. </p><p>The data presented showed that BRII-179, in combination with BRII-835, demonstrated antiviral effects in participants with chronic HBV infection. </p><p>Meanwhile, administering BRII-179 on top of pegylated interferon-alpha improved the overall HBsAg loss rate in 114 virally-suppressed subjects with chronic HBV infection.</p><p>Price (HKD): $1.26, Change: $-0.01, Percent Change: -0.79%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Brii Biosciences Presents Hepatitis B Drug Data at European Medical Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrii Biosciences Presents Hepatitis B Drug Data at European Medical Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-10 19:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Brii Biosciences (HKG:2137) presented new data from two phase 2 studies of BRII-179 for chronic hepatitis B virus infection at the European Association for the Study of the Liver Congress 2024, a June...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02137","symbol_name":"腾盛博药-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2442843850","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2442843850","pubTimestamp":1718018421,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Brii Biosciences  presented new data from two phase 2 studies of BRII-179 for chronic hepatitis B virus infection at the European Association for the Study of the Liver Congress 2024, a June 7 filing on the Hong Kong bourse said. The data presented showed that BRII-179, in combination with BRII-835, demonstrated antiviral effects in participants with chronic HBV infection. Meanwhile, administering BRII-179 on top of pegylated interferon-alpha improved the overall HBsAg loss rate in 114 virally-suppressed subjects with chronic HBV infection.Price : $1.26, Change: $-0.01, Percent Change: -0.79%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02137":"腾盛博药-B","BK4526":"热门中概股","BK1161":"生物科技","BK1574":"生物医药B类股","BK4585":"ETF&股票定投概念","BK1587":"次新股","BK4023":"应用软件","BK4588":"碎股","HKD":"尚乘数科"},"translate_title":"Brii Biosciences在欧洲医学会议上展示乙肝药物数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"02137":0.9},"content_text":"Brii Biosciences (HKG:2137) presented new data from two phase 2 studies of BRII-179 for chronic hepatitis B virus infection at the European Association for the Study of the Liver Congress 2024, a June 7 filing on the Hong Kong bourse said. The data presented showed that BRII-179, in combination with BRII-835, demonstrated antiviral effects in participants with chronic HBV infection. Meanwhile, administering BRII-179 on top of pegylated interferon-alpha improved the overall HBsAg loss rate in 114 virally-suppressed subjects with chronic HBV infection.Price (HKD): $1.26, Change: $-0.01, Percent Change: -0.79%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2442843850"}